Epithelioid Trophoblastic Tumour: A Case with Genetic Linkage to a Child Born over Seventeen Years Prior, Successfully Treated with Surgery and Pembrolizumab
Genre
Journal articleDate
2021-12-13Author
Pisani, DavidCalleja-Agius, Jean
DI FIORE, Riccardo
O'Leary, John J.
Beirne, James J.
O'Toole, Sharon A.
Felix, Ana
Said-Huntingford, Ian
Group
Center for Biotechnology, Sbarro Institute for Cancer Research and Molecular Medicine (Temple University)Permanent link to this record
http://hdl.handle.net/20.500.12613/7620
Metadata
Show full item recordDOI
https://doi.org/10.3390/curroncol28060446Abstract
Epithelioid trophoblastic tumours are rare neoplasms showing differentiation towards the chorion leave-type intermediate cytotrophoblast, with only a handful of cases being reported in the literature. These tumours are slow-growing and are typically confined to the uterus for extended periods of time. While the pathogenesis is unclear, they are thought to arise from a remnant intermediate trophoblast originating from prior normal pregnancies or, less frequently, gestational trophoblastic tumours. A protracted time period between the gestational event and tumour development is typical. This case describes a 49-year-old previously healthy female who presented with a completely asymptomatic uterine mass, discovered incidentally during a routine gynaecological assessment. The pathological analysis of the hysterectomy specimen confirmed an epithelioid trophoblastic tumour, involving the uterus and cervix. This is a rare gynaecological tumour. A comparative short tandem repeat analysis revealed genetic similarities to a previous healthy gestation seventeen years prior. She was successful treated with adjuvant pembrolizumab, with no evidence of disease recurrence to date.Citation
Pisani D, Calleja-Agius J, Di Fiore R, O’Leary JJ, Beirne JP, O’Toole SA, Felix A, Said-Huntingford I. Epithelioid Trophoblastic Tumour: A Case with Genetic Linkage to a Child Born over Seventeen Years Prior, Successfully Treated with Surgery and Pembrolizumab. Current Oncology. 2021; 28(6):5346-5355. https://doi.org/10.3390/curroncol28060446Citation to related work
MDPIHas part
Current Oncology, Vol. 28ADA compliance
For Americans with Disabilities Act (ADA) accommodation, including help with reading this content, please contact scholarshare@temple.eduae974a485f413a2113503eed53cd6c53
http://dx.doi.org/10.34944/dspace/7598